Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:

NCT ID: NCT02897765 Completed - Lung Cancer Clinical Trials

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Start date: October 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate if the treatment with NEO-PV-01 + adjuvant in combination with nivolumab is safe and useful for patients with certain types of cancer. The study also will investigate if NEO-PV-01 + adjuvant with nivolumab may represent a substantial improvement over other available therapies such as nivolumab alone. All eligible patients will receive NEO-PV-01 + adjuvant and nivolumab while on this trial.

NCT ID: NCT02882750 Completed - Lung Cancer Clinical Trials

Effect on Patient Reported Outcomes of VATS and SABR (LILAC)

LILAC
Start date: January 25, 2016
Phase:
Study type: Observational

This study will monitor the effect on patients reported outcomes (PROMs) of VATS resection and SABR for NSCLC delivered at the Leeds Cancer Centre The investigator will support with this information the Shared Decision Making (SDM) process. 300 consecutive patients will be followed up from prior the treatment to 12 months afterwards, administering multiple questionnaires (EORTC QLQ C-30 and LC-13, PSQ-18, Decision Self-Efficacy Scale) by a remote web-based system. Deliverable: 1. Differences after VATS resections or SABR in terms of physical and psychological symptoms, quality of life and satisfaction 2. Patient perspectives of the Shared Decision Making Process.

NCT ID: NCT02872701 Completed - Lung Cancer Clinical Trials

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

Start date: May 4, 2017
Phase: Phase 2
Study type: Interventional

This is a phase 2, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/positron emission tomography imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near Infrared Imaging (NIR) at identifying pulmonary nodules within the operating theater, and to assess the safety and tolerability of single intravenous doses of OTL38.

NCT ID: NCT02871115 Completed - Breast Cancer Clinical Trials

Pilot Study of a Pharmacy Intervention for Older Adults With Cancer

Start date: January 2017
Phase: N/A
Study type: Interventional

The purpose of this research study is to address the challenge of medication management for older patients undergoing treatment for cancer. The sponsor of this protocol is the Massachusetts General Hospital Cancer Center who is providing funding for this research study.

NCT ID: NCT02869789 Completed - Lung Cancer Clinical Trials

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Start date: October 5, 2016
Phase: Phase 4
Study type: Interventional

A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.

NCT ID: NCT02867371 Completed - Lung Cancer Clinical Trials

Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2

EAST2
Start date: August 2016
Phase: N/A
Study type: Interventional

The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs. This study is being conducted to confirm the performance of the Archimedes System in patients who are scheduled for standard bronchoscopy to diagnose highly suspicious lung cancer or metastatic disease. Navigation to and sampling of the patient's lung cancer tumor is conducted.

NCT ID: NCT02853006 Completed - Lung Cancer Clinical Trials

Study on Fluids Associated to Lung Cancer

ECTOPIC/MUTAS
Start date: June 2015
Phase: N/A
Study type: Interventional

The diagnosis of lung cancer is the first cause of cancer deaths for man and woman. It requires invasive procedures (at least endoscopy, transthoracic puncture, or surgery). This study is about the set up of an innovative test for lung cancer prognosis, based on biopsies and surgical material : LungCancerTest, with the creation of a start-up in progress. The main goal of this study is to approve the diagnostic value of the molecular signature of the 26 genes (LungCancerTest) revealed in blood and respiratory fluids among patients with lung cancer.

NCT ID: NCT02852629 Completed - Lung Cancer Clinical Trials

Assessment of a Tool for Decision Making in Case of Worsening Condition of Cancer Patients

CBP-Aggrav
Start date: February 2014
Phase: N/A
Study type: Observational

Observational two year study to evaluate the utility of a decision-support sheet on how to proceed in case of aggravation of a patient's condition with advanced disease.

NCT ID: NCT02851160 Completed - Lung Cancer Clinical Trials

Perceptions and Representations of Cancer Chemotherapy

chemotherapy
Start date: March 2015
Phase: N/A
Study type: Observational

Qualitative study on data from interviews such patients, relatives and doctors involved in the implementation of cancer care. Framework type of method using grounded theory

NCT ID: NCT02847728 Completed - Lung Cancer Clinical Trials

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

Start date: July 28, 2016
Phase:
Study type: Observational

This is an observational, multicenter study in participants treated with nivolumab for the approved indications of melanoma and Lung cancer in Australia, the EU, Switzerland, the United Kingdom (UK), and the United States (US). The targeted countries in the EU for study participation include Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy, Poland, and Spain. Study objectives are to assess the safety experience, survival, adverse event management, and outcomes of adverse events associated with nivolumab in routine oncology care facilities.